SCNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Scienture Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.92−0.44 (-13.10%)
Close on Oct 19, 2026
- Market cap
- $115.68M
- P/E (TTM)
- –
- Dividend yield
- –
Scienture Holdings, Inc. revenue by segment
By business segment
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Integra [Member] | $136.64K | $1.36M | $4.75M | – | – | – | – | 100.0% | -90.0% |
| Trxade, Inc.[Member] | – | $6.40M | $5.44M | $4.92M | $5.55M | $4.53M | $3.41M | – | – |
| Community Specialty Pharmacy LLC [Member] | – | – | $1.18M | $1.65M | $1.65M | $1.89M | $395.42K | – | – |
| Other [Member] | – | – | – | – | – | – | $28.54K | – | – |
| Integra Pharma LLC [Member] | – | – | $4.75M | $3.25M | $9.88M | $1.02M | $28.54K | – | – |
| Other Segments [Member] | – | $19.20K | $60.29K | $62.02K | $44.78K | – | – | – | – |
| Superlatus [Member] | – | $487.02K | – | – | – | – | – | – | – |
By product or service
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product Revenue [Member] | – | $1.85M | $4.75M | – | – | – | – | – | – |
| Service Revenue [Member] | – | $6.42M | $5.50M | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Scienture's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.